Emmaus Life Sciences (EMMA) Stock Price, News & Analysis

Company Overview

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.

Key Stats

• Today's Range: $0.0170 to $0.0170
• 50-Day Range: $0.0120 to $0.0199
• 52-Week Range: $0.00 to $0.10
• Volume: N/A
• Average Volume: 40,213 shs
• Market Capitalization: $1.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

EMMA Stock Analysis - Frequently Asked Questions

How have EMMA shares performed this year?

Emmaus Life Sciences' stock was trading at $0.0085 at the beginning of 2025. Since then, EMMA stock has increased by 100.0% and is now trading at $0.0170.
View the best growth stocks for 2025 here.

How were Emmaus Life Sciences' earnings last quarter?

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) announced its quarterly earnings data on Thursday, May, 15th. The company reported ($0.04) earnings per share for the quarter.

How do I buy shares of Emmaus Life Sciences?

Shares of EMMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Emmaus Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Emmaus Life Sciences investors own include Humanigen (HGEN), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Acasti Pharma (ACST), Actinium Pharmaceuticals (ATNM) and Entasis Therapeutics (ETTX).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 6/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:EMMA
• CIK: 822370
• Web: www.emmausmedical.com
• Phone: (310) 214-0065
• Fax: 866-294-2611
• Employees: 60
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$3.73 million
• Net Margins: -17.11%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -12.66%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.14
• Quick Ratio: 0.12

Sales & Book Value

• Annual Sales: $29.60 million
• Price / Sales: 0.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 63,866,000
• Free Float: 41,513,000
• Market Cap: $1.09 million
• Optionable: Not Optionable
• Beta: 8.11